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Background: The mammalian neurological disorder hereditary hyperekplexia can be attributed to various
mutations of strychnine sensitive glycine receptors. The clinical symptoms of “startle disease” predominantly occur
in the newborn leading to convulsive hypertonia and an exaggerated startle response to unexpected mild stimuli.
Amongst others, point mutations R271Q and R271L in the α1-subunit of strychnine sensitive glycine receptors show
reduced glycine sensitivity and cause the clinical symptoms of hyperekplexia.
Halogenation has been shown to be a crucial structural determinant for the potency of a phenolic compound to
positively modulate glycine receptor function.
The aim of this in vitro study was to characterize the effects of 4-chloropropofol (4-chloro-2,6-dimethylphenol) at
four glycine receptor mutations.
Methods: Glycine receptor subunits were expressed in HEK 293 cells and experiments were performed using the
whole-cell patch-clamp technique.
Results: 4-chloropropofol exerted a positive allosteric modulatory effect in a low sub-nanomolar concentration
range at the wild type receptor (EC50 value of 0.08 ± 0.02 nM) and in a micromolar concentration range at the
mutations (1.3 ± 0.6 μM, 0.1 ± 0.2 μM, 6.0 ± 2.3 μM and 55 ± 28 μM for R271Q, L, K and S267I, respectively).
Conclusions: 4-chloropropofol might be an effective compound for the activation of mutated glycine receptors
in experimental models of startle disease.
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Hereditary hyperekplexia also known as ‘startle disease’,
‘Kok disease’ or ‘stiff baby syndrome’ is a rare hereditary
neurological disorder which is caused by mutations in
genes encoding proteins involved in glycinergic neuro-
transmission, including the α1-subunit of the strychnine
sensitive glycine receptor (GlyR) [1-3]. It predominantly
manifests in the newborn with an extreme exaggerated
hyperexcitability in terms of an abnormal startle re-
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distribution, and reproduction in any mediumsomatosensory stimuli. Patients exhibit an intense
tremor of arms and legs. Frequent falling attacks with
episodes of convulsive hypertonia occur in adult patients
[4,5]. In addition to mutations in the genes GLRB
(encodes glycine receptor β-subunit), SLC6A5 (encodes
glycine transporter 2) and GPHN (encodes the integral
membrane protein gephyrin), mutations in the gene
GLRA1 (encodes the α1-subunit of the GlyR) account
for 40 - 80% of hyperekplexia [6,7]. The most common
mutations reported are R271L or R271Q [8].
Fast inhibitory postsynaptic transmission in the
central nervous system (CNS) is mainly mediated by
γ-aminobutyric acidA (GABAA) receptors, whereas
glycine receptors play a major role in the spinal cord, brain-
stem and retina [9]. The GlyR mutations α1R271Q- andntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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vant symptoms in patients with autosomal dominant
hyperekplexia, characterized by an impaired GlyR-
function due to reduced glycine sensitivity [7,10-12].
The artificial mutation R271K shows the same startle
GlyR features [13,14]. S267 mutations also display
startle symptoms resulting from structural alterations
of the GlyR. The corresponding mutated genes have
been found in hyperekplexic patients and animals
[15,16]. Patients suffering from startle disease are
commonly treated with GABAA-activating drugs like
clonazepam [12]. Clonazepam relieves the symptoms
of hyperekplexia indirectly, but may be accompanied
by sedative side effects [17].
As there is a compelling connection between startle
disease and a distinct GlyR-malfunction, it would be of
benefit to discover selective positive allosteric GlyR-
modulators which might attenuate the hyperekplexic
symptoms by restoring the function of the GlyR. Thus, it
is of interest to modify the molecular structure of propo-
fol in order to optimize all its various (aesthetic, seda-
tive, anticonvulsant) activities or to yield drugs with
more selective actions. The intravenous aesthetic propo-
fol, well known for its positive allosteric modulatory
effects at GABAA-receptors, has been shown to modu-
late glycine receptors in rat cortical and murine spinal
neurons as well as in recombinant expression systems
[18-21]. The effects exhibit a non-selective manner,
i.e. the effects at GlyRs require higher concentrations
than the effect at GABAA-receptors [19]. It has previously
been shown that halogenation of a propofol analogue did
not increase GABA-ergic activity [22,23]. A study of our
group on heterologously expressed α1β glycine receptors
found that 4-chloropropofol is almost 1000-fold more po-
tent than propofol in enhancing glycine induced currents
at wild-type (WT) glycine receptors [24]. The chemical
structures of propofol and its analogue 4-chloropropofol
are illustrated in Figure 1.4-chloropropofol
propofol
Figure 1 Chemical structures of 4-chloropropofol and the
anesthetic propofol. Highlighted structural features are the
non-substituted phenolic hydroxyl group (circle) with the chloride
(red ellipse) in para-position to the hydroxyl group.The aim of this study was to investigate whether
4-chloropropofol improves the function of glycine
receptor mutations relevant for the generation of
hyperekplexia. Consequently, we investigated the effects
of 4-chloropropofol atWTglycine receptors and at the gly-




Human α1-, α1R271Q-, α1R271L-, α1R271K and
α1S267I-GlyR subunits were transiently transfected into
human embryonic kidney cells (HEK 293, ATCC, Mana-
ssas, USA). The wild type α1-GlyR -cDNA was cloned in
pCIS2 (Invitrogen, San Diego, USA) vector and provided
by Prof. Heinrich Betz (Max-Planck-Institut für Hirn-
forschung, Frankfurt am Main, Germany) [25]. For the
plasmid cDNA of the mutated α1R271Q-, α1R271L-,
α1R271K- and α1S267I-GlyR the eukaryotic expression
vector pcDNA1amp (Invitrogen, San Diego, USA), under
the control of cytomegalovirus promoter, was used. For
site-directed mutagenesis, single stranded template
cDNA was synthesized from M13 origin of replication
and the mutations of arginine residue (R) at position 271
to glutamine (R271Q), leucine (R271L) or lysine (R271K)
and mutation of serine residue (S) at position 267 to iso-
leucine (S267I) were generated using standard proce-
dures [26]. The fidelity of the mutagenesis reaction was
confirmed by standard didesoxynucleotide sequencing
(fmol DNA Sequencing System Promega, Southhamp-
ton, UK) and mutated GlyR-cDNA was provided by
Jeremy J. Lambert (Ninewells Hospital and medical
school, Dundee). Wild type and mutated α1-GlyR subu-
nits efficiently form homomeric receptors in heterol-
ogous expression systems [13,25,27].
HEK 293 cells were cultured in medium containing
HAMS’F-12 (Biochrom, Berlin, Germany), supplemented
with 10% fetal bovine serum (FBS, Biochrom, Berlin,
Germany), 100 U ml–1 penicillin and 100μgml–1 strepto-
mycin (Gibco BRL, Life Technologies, Karlsruhe,
Germany) at 37°C in a 5% CO2/ 95% air incubator. For
transfection cells were suspended in a buffer containing
50mM K2HPO4 (Fluka BioChemika, Seelze, Germany),
20mMK-acetate (Sigma-Aldrich, Taufkirchen, Germany)
and 25mM MgSO4 (Sigma-Aldrich, Taufkirchen,
Germany) at pH 7.35. To visualize transfected cells, they
were co-transfected with cDNA encoding for enhanced
green fluorescent protein (EGFP) contained in the
pEGFP-N1 expression vector (Clontech, Palo Alto,
USA). The corresponding cDNA (5μg for the GlyR and
2.5μg for EGFP) was added to 400μl of the cell suspen-
sion and the mixture was rapidly transferred into the
electroporation cuvette. For transfection we used an
electroporation device by EquiBio (Kent, UK) and a
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(Peqlab, Erlangen, Germany).
Transfected cells were replated on 12mm glass cover-
slips (Karl Hecht KG, Sondheim, Germany) in a 24-well-
plate filled with medium and incubated 15–24h before
recording.
Solutions
The phenol derivative 4-chloropropofol (2,6-dimethyl-4-
chlorophenol) was provided as pure substance by Prof.
Paul M. O’Neill (University of Liverpool, England), pre-
pared as light-protected 1M stock solution in ethanol
(EtOH, J.T.Baker, Griesheim, Germany) and stored in
glass vessels at −20°C. The stock solution was directly
dissolved in a low concentrated glycine solution (EC20 –
positive allosteric modulation) or bath solution (direct
activation) to reach the final drug concentration of
1000μM 4-chloropropofol. The investigated concentra-
tions (0.015 nM −100μM) were calculated from the
amount injected into the glass vials. Glycine (Sigma-
Aldrich, Taufkirchen, Germany), 3μM −300mM, was dis-
solved directly into the bath solution.
Drug-containing vials were vigorously vortexed for
30min. Patch electrodes were filled with an intracellular
solution of [mM] KCl 140, MgCl2 2, EGTA 11, HEPES
10, glucose 11, CaCl2 1 with pH 7.3, adjusted with 1 M
KOH and a bath solution contained [mM] NaCl 162,
KCl 5.31, NaHPO4 0.85, KH2PO4 0.22, HEPES 15, glu-
cose 6.11, pH 7.4 adjusted with 1 M NaOH. Osmolarity
of both solutions was set at 280–300 mOsmol.
It has previously been shown that osmotic controls up
to 500mM sucrose produced no currents [13,27].
300 mM glycine adjusted to pH 7.4 by Na-OH revealed
1096mOsm. High glycine solutions of 300 mM glycine
osmolarity subtracted from the osmolarity of the buffer
solution itself, resulted in a total of Δ 800 mOsmol. We
excluded possible osmotic effects of high concentrations
of glycine (up to 300 mM in our experiments) by per-
forming experiments with 1100mM sucrose. These
experiments showed a lack of osmotic effects on HEK
293 cells transfected with WT glycine receptors [see
Additional file 1]. Bath solution itself did not induce
any current amplitude. Thus, any direct effects of
4-chloropropofol in the absence of glycine can be directly
attributed to the applied substance.
Experimental set-up
Whole-cell experiments [28] were performed at a hold-
ing potential of −30 mV with a mean seal resistance of 1
GΩ. Chloride inward currents, due to agonist-induced
channel activation, were resolved in the pA range. A fast
liquid filament switch technique was used for the appli-
cation of the agonist, presented in pulses of 2 s duration
every 20 s. The liquid filament switch technique is ableto exchange the solution passing an outside-out patch or
small whole-cells within 1–2 ms [29,30]. We calculated
flow rate of background solution through the chamber
with 3,4 ml/min corresponding to 4% of maximal pump
rate. With regard to the chamber volume of 100 μl the
exchange solution time within the chamber was assessed
to approximately 1.8 ms, dependent on cell size accord-
ingly. Piezo-switch and small diameter capillary (ID
0.15 mm) within the measurement chamber promoted
the millisecond solution exchange. The correct position-
ing of the cell, in respect to the liquid filament (ID
0.15 mm), was ensured by applying a saturating glycine
pulse (1 mM for WT and S267I, 300 mM for R271Q and
L, 10 mM for R271K) before and after each test experi-
ment [see Additional file 2]. The induced current (I) by
this saturating control solution was defined as Icontrol.
Care was taken that the amplitude and shape of the gly-
cine induced control currents had stabilized before pro-
ceeding with the experiment. The stability of the seal
was controlled during the complete experiment via con-
trol of the seal resistance. A variation of 10-20% of the
basic value was regarded as tolerable. Test solution and
the saturating glycine solution were applied via the same
glass-polytetrafluoroethylene perfusion system, but from
separate reservoirs.
4-chloropropofol was applied either alone, in order to
determine its direct agonistic effects at the GlyR muta-
tions or in combination with a sub-saturating (EC20) gly-
cine concentration (20 μM for WT, 10 mM for R271Q,
30 mM for R271L, 100 μM for R271K and 30 μM for
S267I), in order to determine its glycine modulatory
effects. A new cell was used for each protocol and at
least four different experiments were performed for each
condition. The concentration of the diluent EtOH corre-
sponding to the highest drug concentration used was
17150 μM. We have performed experiments demonstrat-
ing the lack of effect of ethanol on the potentiation of
glycine induced currents in this concentration [see
Additional file 3].
Current recording and analysis
For data acquisition we used an EPC 10 digitally-
controlled amplifier in combination with Patch Master
Software (HEKA Electronics, Lambrecht, Germany). Cur-
rents were filtered at 2 kHz. Analysis was performed using
Fit Master (HEKA Electronics, Lambrecht, Germany) and
Graph Prism 5.0 software (GraphPad, La Jolla, USA).
Fitting procedures were performed using a non-linear
least-squares Marquardt-Levenberg algorithm.
The concentration-response-curves for receptor acti-
vation by the natural agonist and for positive allosteric
modulation by 4-chloropropofol were fitted according to
the Hill function (Inorm = [1 + (EC50/[C])
nH ]–1). Inorm is
the current induced by the respective concentration [C]
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ture. EC50 is the concentration required to evoke a re-
sponse amounting to 50% of their own maximal
response and nH is the Hill coefficient. For 4-chloropro-
pofol, the dose–response curves did not always reach a
plateau response, because 4-chloropropofol in high con-
centrations leads to a decline in seal resistance and thus,
did not yield reliable results. Therefore, further curve
process could not be described by the Hill function. In
these cases, the maximum response was the response at
the highest concentration of the test compound for
which a reliable response could be recorded.
KS normality test showed no normal distribution for
the calculated EC50 values; consequently two-tailed
Mann–Whitney U test was performed to determine sig-
nificance. All columns depicted in the diagram are
means ± SEM and the levels of significance are indicated
as *p < 0.05 and **p < 0.01.
Positive allosteric modulation of 4-chloropropofol was
expressed as percentage of the current elicited by the
sub-saturating glycine solution according to E (%) = 100
[(I-I0)/I0], where I0 is the current response to the sub-
saturating glycine solution. Currents were normalized to
their own maximum response. The rise time τ (ms) of
the initial glycine current traces (10-90% of the maximal
amplitude Imax) were determined with a monoexponen-
tial fit (Fitmaster, HEKA Electronics) [31]. Data in tables
and figures as well in the following results section are
shown as mean values ± SEM.
A total of 90 cells was included in the study for the in-
vestigation of glycine sensitivity (n = 42) and modulating
effects (n = 48) of mutant and WT glycine receptors.
Cells that did not show a stable seal till the end of the
experiment were excluded for EC50 calculation. Thus,
the cells included in the calculation of Imax and rise time
values of the peak amplitude may differ in the total









Figure 2 Dose–response curves for receptor activation by the natural
with the indicated parameters. The EC50 value defines the effect at half-m
coefficient.each test experiment, are provided in the appropriate
figures and tables.
Results
In our study we were able to characterize glycine sensi-
tivity and modulating effects (positive allosteric modula-
tion and direct activation) of α1 glycine receptors and its
mutations R271Q, L, K and S267I by 4-chloropropofol.
Glycine sensitivity
Glycine induced larger inward currents in HEK293-cells
expressing WT glycine receptors than the startle disease
mutations α1R271Q, α1R271L and α1R271K, following
application of a saturating concentration of the natural
agonist. Consequently, the glycine sensitivity of the
mutations to the natural agonist glycine was consider-
ably reduced [see Additional file 4]. Glycine induced in-
ward currents at S267I are only marginally reduced in
amplitude compared to the WT. The current transient
at the WT showed a biphasic time course with a fast in-
crease, followed by a monophasic decay. These charac-
teristics were considerably changed at the startle
receptors, whereas R271K reflected to a greater extent
the WT. S267I shows nearly similar rise time values
compared to the WT. Concentration-response curves
are depicted in Figure 2. EC50 values and corresponding
Hill coefficients (nH), as well as rise time values and
mean maximal current amplitudes are shown in Table 1.
Positive allosteric modulation and direct-activating effects
of 4-chloropropofol
4-chloropropofol potentiated the response of a sub-
saturating glycine solution (EC20) in a concentration
dependent manner resulting in EC50 values in the low
sub-nanomolar concentration range at the wild type, in








agonist glycine. Solid lines are Hill fits to the data (mean ± SEM)
aximal activation and nH represents the corresponding Hill
Table 1 Glycine sensitivity at the WT and mutated glycine receptors






[% of mean WT
current amplitude] ± SEM
WT 0.04±0.02 0.8±0.7 7 1645±426 3.7±0.8 100.0±26
R271Q 26.3±17.7 1.0±0.6 6 123±19 673±224 7.5±15
R271L 102.1±15.0 1.8±0.7 5 336±51 998±129 20.5±12
R271K 0.43±0.29 1.0±0.5 6 526±97 14.9±7.7 32.0±18
S267I 0.12±0.05 1.1±0.2 4 1122±765 6.6±2.5 68.2±68
EC50 values, corresponding Hill coefficients (nH) as well as rise time values and mean maximal current amplitudes are depicted for glycine receptor activation by
the natural agonist glycine.
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Concentration-response curves, representative current
traces, EC50 values and corresponding Hill coefficients
(nH), as well as maximal positive allosteric modulation



















Figure 3 Representative current traces for positive allosteric modulat
mutated α1-glycine receptors. Traces elicited by a 2 s co-application of a
R271Q, 30 mM R271L and 100 μM R271K) and 4-chloropropofol. Respective
S267I), 300 mM (R271Q and R271L) and 10 mM (R271K) respectively, glycin
response evoked by glycine (second trace from top) in a concentration deDirect activation of the GlyR mutations by 4-
chloropropofol (0.01-1000 μM) in the absence of the
natural agonist glycine is inconsistent. At R271K we
found a dose-dependent current increase (EC50 = 16.4 ±
22.3 μM, nH 0.41 ± 0.15, n = 5) with a mean maximal ac-




























ion of glycine induced currents by 4-chloropropofol at WT and
sub-saturating glycine solution (EC20 = 10 μM WT, 30 μM S267I, 10 mM
upper traces show the maximal current elicited by a 1 mM (WT and
e control solution. 4-chloropropofol increased the amplitude of the
















Figure 4 Dose–response curves for positive allosteric modulation of glycine induced currents by 4-chloropropofol. Solid lines are Hill fits
to the data (mean ± SEM) with the indicated parameters. The EC50 value defines the effect at half-maximal activation and nH represents the
corresponding Hill coefficient.
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completely insensitive to the direct effects of 4-
chloropropofol (Figure 5).
The significant differences of calculated EC50 values
for positive allosteric modulation of 4-chloropropofol at
the four startle mutations and the WT are shown in a
mean-standard deviation-plot in Figure 6.Discussion
This study provides evidence that the para-substituted
propofol derivative 4-chloropropofol effectively modu-
lates the WT GlyR and the α1R271Q, α1R271L-
α1R271K- and S267I-GlyR startle mutations in vitro.
4-chloropropofol appears to be much more potent
than propofol at the WT GlyR and at the mutation
S267I [21].
These findings show a potential role for halogenated
propofol derivatives in restoring the reduced function of
mutated glycine receptors, which might alleviate the
symptoms of the reduced glycinergic inhibition in ex-
perimental models of hyperekplexia. In a previous studyTable 2 Positive allosteric modulation of
4-chloropropofol at GlyR/mutations
4-chloropropofol positive allosteric modulation




WT 0.08 ± 0.02 nM 2.0 ± 2.8 4 269 ± 88
R271Q 1.3 ± 0.6μM 0.9 ± 1.3 5 260 ± 52
R271L 0.1 ± 0.2μM 0.7 ± 0.3 6 153 ± 46
R271K 6.0 ± 2.3μM 0.3 ± 0.1 6 231 ± 174
S267I 55.1 ± 28.4μM 0.7 ± 0.3 4 128 ± 14
EC50 values and Hill coefficients for receptor modulation by 4-chloropropofol
derived from fits of the Hill equation to the normalized current response as
well as values for maximal positive allosteric modulation at WT and mutated
glycine receptors.we have shown that the halogenation of phenol
derivatives is crucial for effective, positive allosteric
modulation of the GlyR [32]. Thus, it was our aim to
find a substance able to enhance the reduced glycinergic
inhibition by pharmacological modulation of mutated
receptors.
Positive allosteric modulation of WT and mutated GlyR
with impaired glycine sensitivity by 4-chloropropofol
We were able to demonstrate the strongly reduced gly-
cine sensitivity of the mutated receptors associated with
lower maximal inducible current amplitudes and higher
EC50 values for glycine compared to the WT [8,13,27].
Hill slope values for alpha1 glycine receptors in HEK293
are known to show cooperativity and described to amount
nH 2.4 for human [33]and nH 3.3 for rat alpha 1 GlyR
[34]. The remarkably reduced nH values of our study (nH
0.8 for WT) may be due to differences in drug application
speed and set up mode. The prolonged rise time of 3.7 ms
for WT (vs. 0.4 ms on cell mode, 4 s drug application [35]
also corroborates this hypothesis. Nevertheless, the elon-
gated rise time values of hyperekplexic glycine receptors
compared to the WT are appreciable. Our results clarify
the importance of amino acid position R271 in the trans-
membrane domain 2 (TM2) of the α1 subunit for the allo-
steric modulation of the GlyR [36]. R271 determines the
channel properties for chloride binding and entry [11,12]
and is thought to be involved in channel gating [37] and
ion permeation [38]. The mutations at R271 lead to a
reduced chloride conductivity at mutated startle receptors
whereas the influence on assembly and oligomerisation of
the GlyR is reported to be negligible [13]. Charge reversal
mutations of positive charged amino acids in the TM2 of
the α1 subunit have been published to reduce single chan-
nel conductance by 41% [39].
4-chloropropofol effectively potentiated glycine-
induced currents at the mutations R271Q, R271L and


































Figure 5 Representative current traces for direct activation of 4-chloropropofol at startle receptors in the absence of natural agonist
glycine. Representative current traces are depicted as follows: first trace saturating glycine control and subsequent traces different doses of
4-chloropropofol.
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function was detected in the low-micromolar and sub-
micromolar concentration range. Furthermore, our study
shows that halogenation of the anesthetic propofol yields
a compound with a highly increased potency for activa-
tion of chloride currents via WT and mutated α1 glycine
receptors. 4-chloropropofol shows a more than 1000-
fold increased potency to positively modulate glycine
induced chloride currents at WT glycine receptors in
comparison to the effect of propofol [21].
A recent study provided evidence that hyperekplexic
R271L glycine receptors did not significantly change
propofol binding and its strychnine cooperativity in
comparison to the WT [40]. Our experiments revealed
highly increased EC50 values for modulation of the
mutated receptors R271Q, R271L and R271K-GlyR by 4-
chloropropofol compared to the effect at the WT.
S267 seems to be crucial for 4-chloropropofol
binding pocket
Point mutations in the α1 subunit at the amino acid pos-
ition Arg271, mainly R271Q- and R271L-GlyR, aremutations leading to clinical symptoms of the impaired
GlyR function in startle disease [7]. The arginine (R) at
position 271 of the α1GlyR is substituted by glutamine
(Q) or leucine (L), respectively. The substitution of ar-
ginine to lysine (K) leads to the artificial mutation
R271K, which also shows the typical startle GlyR fea-
tures [13,14,27]. Mutation of the serine residue at pos-
ition 267 is relevant for hyperekplexia as well and an
exchange to isoleucine (S267I) diminishes binding of the
anesthetic propofol [10,39]. S267 has previously been
shown to be crucial for binding of propofol, ethanol and
halogenated anesthetics [21,41,42]. Our results show,
that S267 may be a part of the binding pocket cavity for
4-chloropropofol at the glycine receptor.
Compared to propofol [27], the increase in efficacy of
4-chloropropofol at hyperekplexic receptors in this study
may be explained due to an interaction at R271 with the
halogen (via a possible ion dipole interaction), additive
to the already supposed binding site of propofol through
the intact S267 (hydrogen bond). Further, more detailed
structure-binding analysis will be necessary to substanti-
ate these interactions. Evidence for the importance of
Figure 6 Mean-standard deviation plot of the calculated EC50
values (mean ± SD) at either α1-(WT) or mutations -R271Q,
-R271L, -R271K and -S267I expressed in HEK293 cells following
application of 4-chloropropofol. P-values of Mann–Whitney U test
result in significant differences between EC50 of WT and the
corresponding GlyR-mutation, indicated as significance levels of
*p<0.05 and **p<0.01 (WT vs. R271Q, p=0.0159; WT vs. R271L as well
as vs. R271K, p = 0.0095 and WT vs. S267I, p = 0.0286; n = 4–6 per
group).
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from a study showing that α1S267Q-GlyR knock-in mice
displayed a hyperekplexic phenotype and were shown to
disrupt normal GlyR function [16]. Recently, it has been
found in a hyperekplexic family that a S267N point mu-
tation influences agonist responses and ethanol modula-
tion of the mutated receptor [15].
The nature of the TM2 residue (267) of the glycine α1
subunit influences the glycine modulatory effect of pro-
pofol and direct activation of the receptor by this
anesthetic [21]. A comparison of the impact of such
mutations on the interaction of 4-chloropropofol with
glycine and GABAA receptors should permit a better
understanding of the molecular determinants of action
of 4-chloropropofol on these structurally related recep-
tors and may aid the development of selective modula-
tors of mutated startle disease receptors.
These in vitro findings are based on homomeric human
α1-glycine receptors. Glycinergic-neurotransmission inadults is mainly based on heteromeric α1β-receptors [43].
The GlyR is a ligand gated ion-channel composed of five
subunits [44], comprising 2α and 3β subunits [45]. Four
different α isoforms exist (α1-α4) which show a develop-
mental and regional dependant distribution [46]. Co-
expression of the α subunit has an impact on the effect of
various agonists (among them the natural agonist glycine),
whereas its influence on the effects of strychnine seems to
be negligible [45]. Other studies revealed that the expres-
sion of homomeric α1 subunits in mammalian cells or
Xenopus laevis oocytes is sufficient to generate functional
receptors with pharmacological properties that are typical
for the native GlyR in the spinal cord [47,48]. We have
previously shown that co-expression of the glycine β sub-
unit does not affect the response of heterologously
expressed WT α1 subunits to different halogenated phenol
derivatives and propofol [21,32]. Additionally, studies with
startle disease transgenic mice showed only a small level
(25% of normal) of β subunits to be necessary for a proper
GlyR-function [49].
Recessive GLRA1 mutations as being caused by non-
sense or frameshift mutations in the α1 gene have been
increasingly associated with case reports elucidating the
molecular genetics of hyperekplexia [6] As autosomal
dominant (AD) startle mutations of GLRA1 such as mis-
sense mutations R271Q and R271L define case reports
with high frequency in hyperekplexic patients, it is im-
portant to mention that these AD cases represent only 5
of 30 index cases as recently published [6]. Cell surface
expression and Imax of recessive GLRA1 mutations are
markedly reduced compared to AD mutations. It would
be an interesting attempt in functional analysis of 4-
chloropropofol to investigate the effects of 4-chloro-
PRO at recessive startle mutations.
In vivo effects of 4-chloropropofol in experimental
models of startle disease
The impact of glycine receptor modulation by propofol
on the clinical effects remains an interesting, yet unre-
solved issue. Evidence that an effect on glycine receptors
may occur in vivo comes from other studies of the star-
tle disease. The intravenous anesthetic propofol is
known to activate glycine-induced currents in startle
mutations in vitro and emerged as a transient treatment
of startle symptoms in a transgenic mouse line carrying
the R217Q mutation (tg271Q-300). Patch-clamp experi-
ments at different startle mutations expressed in Xen-
opus laevis oocytes revealed that propofol in the
concentration range of 1–500 μM increases the glycine
induced maximal response. Transgenic mice (tg271Q-
300) exhibited a decreased righting time and abatements
in tremor without sedative side effects following injec-
tions of low doses of propofol (15 mg/kg i.p.) [27]. We
have detected EC50 values for modulation of the startle
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lower concentration range. Thus, it is conceivable that
4-chloropropofol might act in sub-anesthetic doses at
startle disease glycine receptors.Conclusions
In summary, our results broaden the body of knowledge
about approaches to restore the reduced glycinergic in-
hibition in startle disease. In particular, 4-chloropropofol
might lead to an effective enhancement of the function
of startle disease glycine receptors in vitro. Based on our
results we hypothesize that 4-chloropropofol might alle-
viate hyperekplexic symptoms in animal models of star-
tle disease.Additional files
Additional file 1: Osmolarity controls. Whole cell experiments at
α1R271Q- glycine receptors lack activation following 1100 mM glucose
application. High glycine solutions of 300 mM glycine adjusted to pH 7.4
by Na-OH revealed 1096 mOsm. 300 mM glycine osmolarity subtracted
from the osmolarity of the buffer solution itself, resulted in a total of Δ
800 mOsmol. Switch to 1100 mM glucose rather reduces baseline leak
currents following 2 s application. In addition wild type glycine receptors
didn’t show sensitivity for osmolarity controls (600 mM sucrose). Thus
osmolarity effects resulting from high glycine concentrations up to
300 mM at startle glycine receptor mutations can be excluded.
Additional file 2: Control of rundown effects of glycine receptors.
Current amplitude of glycine control (10 mM) traces applied before and
after application of 4-chloropropofol at α1R271K-mutation remains
almost unchanged with negligible run down in liquid filament switch
technique. Same picture for subsequent application of subsaturating
glycine solution (10 μM) before and after co-application of 17.15 mM
ethanol in custom-designed gravity driven perfusion system. There is
almost no change in amplitude size. In any case the addition of ATP to
the pipette solution should help to reduce receptor desensibilisation to
exclude rundown effects for future studies.
Additional file 3: Ethanol control experiments. Ethanol (17.15 mM) in
a sub-saturating glycine solution (10 μM) doesn’t lead to an additional
activation of wild type glycine receptors, by contrast the initial sub-
saturating glycine response is reduced when ethanol is added.
Consequently the ethanol effect in particular at high 4-chloropropofol
doses (where the concentration of the diluent EtOH corresponding to
the highest drug concentration is 17.15 mM) has no influence on
4-chloropropofol effect.
Additional file 4: Glycine sensitivity at R271Q. α1R271Q-mutation
lacks activation by low glycine concentrations (10-100 μM). Dose
response curve starts with current peaks of less than 50 pA at 1 mM
glycine. These current traces are depicted as example to illustrate
repressed glycine sensitivity of mutated startle receptors.Competing interests
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